Galena raises $35m for Abstral, NeuVax
This article was originally published in Scrip
Executive Summary
Galena Biopharma will use proceeds from a $35m public offering to fund commercialization of the breakthrough cancer pain drug Abstral (fentanyl sublingual tablets) and late-stage development of its cancer vaccine Neuvax (nelipepimut-S), among other expenses.